Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration

Authors

Dong-Young Choi, Myung-Koo Lee, Jin Tae Hong

Abstract

Constitutive expression of C-C chemokine receptor (CCR) 5 has been detected in astrocytes, microglia and neurons, but its physiological roles in the central nervous system are obscure. The bidirectional interactions between neuron and glial cells through CCR5 and its ligands were thought to be crucial for maintaining normal neuronal activities. No study has described function of CCR5 in the dopaminergic neurodegeneration in Parkinson's disease. In order to examine effects of CCR5 on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration, we employed CCR5 wild type (WT) and knockout (KO) mice. Immunostainings for tyrosine hydroxylase (TH) exhibited that CCR5 KO mice had lower number of TH-positive neurons even in the absence of MPTP. Difference in MPTP (15 mg/kg × 4 times, 2 hr interval)-mediated loss of TH-positive neurons was subtle between CCR5 WT and KO mice, but there was larger dopamine depletion, behavioral impairments and microglial activation in CCR5 deficient mice. Intriguingly, CCR5 KO brains contained higher immunoreactivity for monoamine oxidase (MAO) B which was mainly localized within astrocytes. In agreement with upregulation of MAO B, concentration of MPP + was higher in the substantia nigra and striatum of CCR5 KO mice after MPTP injection. We found remarkable activation of p38 MAPK in CCR5 deficient mice, which positively regulates MAO B expression. These results indicate that CCR5 deficiency modifies the nigrostriatal dopaminergic neuronal system and bidirectional interaction between neurons and glial cells via CCR5 might be important for dopaminergic neuronal survival.

Link to Article

http://dx.doi.org/10.1016/j.nbd.2012.08.001

Microcrack Density and Nanomechanical Properties in the Subchondral Region of the Immature Piglet Femoral Head following Ischemic Osteonecrosis

Authors

Olumide O. Aruwajoye, Mihir K. Patel, Matthew R. Allen, David B. Burr, Pranesh B. Aswath, Harry K.W. Kim

Abstract

Development of a subchondral fracture is one of the earliest signs of structural failure of the immature femoral head following ischemic osteonecrosis, and this eventually leads to a flattening deformity of the femoral head. The mechanical and mineralization changes in the femoral head preceding subchondral fracture have not been elucidated. We hypothesized that ischemic osteonecrosis leads to early material and mechanical alterations in the bone of the subchondral region. The purpose of this investigation was to assess the bone of the subchondral region for changes in the histology of bone cells, microcrack density, mineral content, and nanoindentation properties at an early stage of ischemic osteonecrosis in a piglet model. This large animal model has been shown to develop a subchondral fracture and femoral head deformity resembling juvenile femoral head osteonecrosis. The unoperated, left femoral head of each piglet (n = 8) was used as a normal control, while the right side had a surgical ischemia induced by disrupting the femoral neck vessels with a ligature. Hematoxylin and eosin (H&E) staining and TUNEL assay were performed on femoral heads from 3 piglets. Quantitative backscattered electron imaging, nanoindentation, and microcrack assessments were performed on the subchondral region of both control and ischemic femoral heads from 5 piglets. H&E staining and TUNEL assay showed extensive cell death and an absence of osteoblasts in the ischemic side compared to the normal control. Microcrack density in the ischemic side (3.2 ± 0.79 cracks/mm2) was significantly higher compared to the normal side (0.27 ± 0.27 cracks/mm2) in the subchondral region (p < 0.05). The weighted mean of the weight percent distribution of calcium (CaMean) also was significantly higher in the ischemic subchondral region (p < 0.05). Furthermore, the nanoindentation modulus within localized areas of subchondral bone was significantly increased in the ischemic side (16.8 ± 2.7 GPa) compared to the normal control (13.3 ± 3.2 GPa) (p < 0.05). Taken together, these results support the hypothesis that the nanoindentation modulus of the subchondral trabecular bone is increased in the early stage of ischemic osteonecrosis of the immature femoral head and makes it more susceptible to microcrack formation. We postulate that continued loading of the hip joint when there is a lack of bone cells to repair the microcracks due to ischemic osteonecrosis leads to microcrack accumulation and subsequent subchondral fracture.

Link to Article

http://dx.doi.org/10.1016/j.bone.2012.07.028

Protective Roles of DMP1 in High Phosphate Homeostasis

Authors

Afsaneh Rangiani, Zhengguo Cao, Yao Sun, Yongbo Lu, Tian Gao, Baozhi Yuan, Anika Rodgers, Chunlin Qin, Makoto Kuro-o, Jian Q. Feng

Abstract

Dmp1 (dentin matrix protein1) null mice (Dmp1−/−) display hypophosphatemic rickets with a sharp increase in fibroblast growth factor 23 (FGF23). Disruption of Klotho (the obligatory co-receptor of FGF23) results in hyperphosphatemia with ectopic calcifications formed in blood vessels and kidneys. To determine the role of DMP1 in both a hyperphosphatemic environment and within the ectopic calcifications, we created Dmp1/Klothocompound deficient (Dmp1−/−kl/kl) mice. A combination of TUNEL, immunohistochemistry, TRAP, von Kossa, micro CT, bone histomorphometry, serum biochemistry and Scanning Electron Microscopy techniques were used to analyze the changes in blood vessels, kidney and bone for wild type control, Dmp1−/−,Klothodeficient (kl/kl) and Dmp1−/−kl/kl animals. Interestingly, Dmp1−/−kl/kl mice show a dramatic improvement of rickets and an identical serum biochemical phenotype to kl/kl mice (extremely high FGF23, hyperphosphatemia and reduced parathyroid hormone (PTH) levels). Unexpectedly, Dmp1−/−kl/kl mice presented elevated levels of apoptosis in osteocytes, endothelial and vascular smooth muscle cells in small and large blood vessels, and within the kidney as well as dramatic increase in ectopic calcification in all these tissues, as compared tokl/kl. These findings suggest that DMP1 has an anti-apoptotic role in hyperphosphatemia. Discovering this novel protective role of DMP1 may have clinical relevance in protecting the cells from apoptosis in high-phosphate environments as observed in chronic kidney disease (CKD).

Link to Article

http://dx.doi.org/10.1371/journal.pone.0042329

Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta

Authors

Benjamin P. Sinder, Mary M. Eddy, Michael S Ominsky, Michelle S. Caird, Joan C. Marini, Kenneth M. Kozloff

Abstract

Osteogenesis imperfecta (OI) is a genetic bone dysplasia characterized by osteopenia and easy susceptibility to fracture. Symptoms are most prominent during childhood. Although anti-resorptive bisphosphonates have been widely used to treat pediatric OI, controlled trials showed improved vertebral parameters but equivocal effects on long-bone fracture rates. New treatments for OI are needed to increase bone mass throughout the skeleton. Sclerostin antibody (Scl-Ab) therapy is potently anabolic in the skeleton by stimulating osteoblasts via the canonical wnt signaling pathway, and may be beneficial for treating OI. In this study, Scl-Ab therapy was investigated in mice heterozygous for a typical OI-causing Gly- > Cys substitution incol1a1. Two weeks of Scl-Ab successfully stimulated osteoblast bone formation in Brtl/+ and WT mice, leading to improved bone mass and reduced long-bone fragility. Image-guided nanoindentation revealed no alteration in local tissue mineralization dynamics with Scl-Ab. These results contrast with previous findings of antiresorptive efficacy in OI both in mechanism and potency of effects on fragility. In conclusion, short-term Scl-Ab was successfully anabolic in osteoblasts harboring a typical OI-causing collagen mutation and represents a potential new therapy to improve bone mass and reduce fractures in pediatric OI.

Link to Article

http://dx.doi.org/10.1002/jbmr.1717

In vivo bone-specific EphB4 overexpression in mice protects both subchondral bone and cartilage during osteoarthritis

Authors

Gladys Valverde-Franco PhD, Jean-Pierre Pelletier MD, Hassan Fahmi PhD, David Hum MSc, Koichi Matsuo MD, PhD, Bertrand Lussier DVM, MSc, Dipl. ACVS, Mohit Kapoor PhD, Johanne Martel-Pelletier PhD

Abstract

In vitro activation of the receptor EphB4 positively impacts human osteoarthritis (OA) articular cell metabolism. However, the specific in vivo role of this ephrin receptor in OA remains unknown. We investigated in mice the in vivo effect of bone-specific EphB4 overexpression on OA pathophysiology. Morphometric, morphological, and radiological evaluations were performed on postnatal day 5 (P5) and on 10-week-old mice. Knee OA was surgically induced (DMM) in 10-week-old male EphB4 homozygous (TgEphB4) and wild-type (WT) mice. Medial compartment evaluations of cartilage were performed using histology and immunohistochemistry, and of subchondral bone using histomorphometry, osteoclast staining, and micro-computed tomography. There was no obvious phenotypic difference in skeletal development between TgEphB4 and WT mice at P5 and 10 weeks. At 8 and 12 weeks post-DMM surgery, TgEphB4 mice demonstrated significantly less cartilage alteration than the WT in the medial tibial plateau and the femoral condyle. This was associated with a significant reduction in the operated TgEphB4 mice of aggrecan and type II collagen degradation products, type X collagen and collagen fibril disorganization. The medial tibial subchondral bone demonstrated at both times post-DMM surgery that, compared to the WT, the TgEphB4 mice had a significant reduction in sclerosis, bone volume, trabecular thickness, and number of tartrate resistant acid phosphatase positive osteoclasts.This is the first in vivo evidence that bone-specific EphB4 overexpression exerts a protective effect on OA joint structural changes. This study stresses the in vivo importance of subchondral bone biology in cartilage integrity.

Link to Article

http://dx.doi.org/10.1002/art.34638

BMP-2 tethered hydroxyapatite for bone tissue regeneration: Coating chemistry and osteoblast attachment

Authors

Stefanie M. Shiels, Kimberly D. Solomon, Marcello Pilia, Mark R. Appleford, Joo L. Ong

Abstract

The goal of this study was to determine the effectiveness of using polyethyleneimine (PEI) and a polyethylene glycol (PEG) tether to bind human recombinant bone morphogenetic protein-2 (rhBMP-2) to hydroxyapatite (HAp) to enhance rhBMP-2 loading, alter its release properties, and enhance cellular interaction with the material. By using a branched PEI that was derived to express free thiols, rhBMP-2 was coated onto dense HAp surfaces at ∼43 ng/cm2. Using this novel attachment methodology, it was observed that the PEI-SH coating did not change the morphology of the HAp surfaces and that the amount of rhBMP-2 loaded was comparable to a direct adsorption method. In addition, it was also observed that the PEI and PEG tether significantly retained the rhBMP-2 to the HAp surface, inhibiting the burst release effect. Using human fetal osteoblast cells, the PEI- and PEG-tethered BMP-2 was also observed to increase cellular attachment by 10-fold when compared with uncoated HAp and adsorbed rhBMP-2. It was concluded from this study that PEI and PEG tether significantly reduce the initial burst release effect of rhBMP-2. It was also concluded that the rhBMP-2 conjugation to PEI and PEG tether promoted an increase in cellular attachment to the HAp surface.

Link to Article

http://dx.doi.org/10.1002/jbm.a.34241